﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>3</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2013</Year>
        <Month>06</Month>
        <DAY>30</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Affinity Purification of Tumor Necrosis Factor-α Expressed in Raji Cells by Produced scFv Antibody Coupled CNBr-Activated Sepharose</ArticleTitle>
    <FirstPage>19</FirstPage>
    <LastPage>23</LastPage>
    <ELocationID EIdType="doi">10.5681/apb.2013.004</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Jalal</FirstName>
        <LastName>Abdolalizadeh</LastName>
      </Author>
      <Author>
        <FirstName>Jafar</FirstName>
        <LastName>Majidi Zolbanin</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Nouri</LastName>
      </Author>
      <Author>
        <FirstName>Behzad</FirstName>
        <LastName>Baradaran</LastName>
      </Author>
      <Author>
        <FirstName>AliAkbar</FirstName>
        <LastName>Movassaghpour</LastName>
      </Author>
      <Author>
        <FirstName>Safar</FirstName>
        <LastName>Farajnia</LastName>
      </Author>
      <Author>
        <FirstName>Yadollah</FirstName>
        <LastName>Omidi</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.5681/apb.2013.004</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2012</Year>
        <Month>09</Month>
        <Day>26</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: Recombinant tumor necrosis factor-alpha (TNF-α) has been utilized as an antineoplastic agent for the treatment of patients with melanoma and sarcoma. It targets tumor cell antigens by impressing tumor-associated vessels. Protein purification with affinity chromatography has been widely used in the downstream processing of pharmaceutical-grade proteins. Methods: In this study, we examined the potential of our produced anti-TNF-α scFv fragments for purification of TNF-α produced by Raji cells. The Raji cells were induced by lipopolysaccharides (LPS) to express TNF-α. Western blotting and Fluorescence-activated cell sorting (FACS) flow cytometry analyses were used to evaluate the TNF-α expression. The anti-TNF-α scFv selected from antibody phage display library was coupled to CNBr-activated sepharose 4B beads used for affinity purification of expressed TNF-α and the purity of the protein was assessed by SDS-PAGE. Results: Western blot and FACS flow cytometry analyses showed the successful expression of TNF-α with Raji cells. SDS-PAGE analysis showed the performance of scFv for purification of TNF-α protein with purity over 95%. Conclusion: These findings confirm not only the potential of the produced scFv antibody fragments but also this highly pure recombinant TNF-α protein can be applied for various in vitro and in vivo applications.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">TNF-α expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Affinity Purification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Monoclonal antibody</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">LPS</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>